Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

20.08.2018 | consensus report | Ausgabe 23-24/2018 Open Access

Wiener klinische Wochenschrift 23-24/2018

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding

Wiener klinische Wochenschrift > Ausgabe 23-24/2018
MD Prof. Dr. Thomas Gremmel, MD Prof. Dr. Alexander Niessner, Hans Domanovits, Martin Frossard, Gürkan Sengölge, Barbara Steinlechner, Thomas Sycha, Michael Wolzt, MD Prof. Dr. Ingrid Pabinger
Wichtige Hinweise
T. Gremmel and A. Niessner share first authorship and are listed in alphabetical order.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s00508-019-1467-8.


The non-vitamin K antagonist oral anticoagulants (NOACs) have considerably changed clinical practice and are increasingly being used as an alternative to vitamin K antagonists (VKAs) for 3 main reasons: 1) an improved benefit-risk ratio (in particular lower rates of intracranial bleeding), 2) a more predictable effect without the need for routine monitoring, and 3) fewer food and drug interactions compared with VKAs. Currently, there are four NOACs available: the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the thrombin inhibitor dabigatran. This consensus paper reviews the properties and usage of NOACs in a number of high-risk patient populations, such as patients with chronic kidney disease, patients ≥80 years of age and others and provides guidance for the use of NOACs in patients at risk of bleeding.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 23-24/2018

Wiener klinische Wochenschrift 23-24/2018 Zur Ausgabe

images in clinical medicine

Intuity™ aortic valve thrombosis

mitteilungen der gesellschaft der ärzte in wien